Gritstone Fails Cancer Vaccine Trial, Plans Phase III and Public Offering
02 Apr 2024
VaccinePhase 2Clinical ResultPhase 3mRNA
Pictured: Gloved hand holds cancer vaccine vial/iStock, Cindy Shebley
Despite mixed mid-stage data, Gritstone bio is determined to head to Phase III with its personalized cancer vaccine. The biotech’s stock took a 32% pre-trading plummet Tuesday morning after the preliminary data drop was immediately followed by a public offering announcement.
GRANITE is Gritstone’s first oncology program. It’s being tested in patients with newly diagnosed, metastatic microsatellite-stable colorectal cancer (MSS-CRC) following a chemotherapy regimen with bevacizumab.
Patients in the open-label Phase II/III trial showed an early trend toward benefit for GRANITE. However, a short-term circulating tumor DNA (ctDNA) response analysis did not demonstrate a difference in the 39 patients treated versus the 28 in the control arm. Patients on the GRANITE vaccine regimen showed a molecular response of 30%, while the control arm came in at 41.7%. Gritstone pointed to the unanticipated continuation of the drop in ctDNA from induction chemotherapy in both arms, which generated similar short-term response rates.
“We simply got it wrong,” Gritstone CEO Andrew Allen said in a statement, acknowledging the inherent risk of “pioneering new spaces.”
Gritstone contends that a long-term analysis of more mature progression-free survival data in the third quarter will still lead to a Phase III regulatory discussion. Median PFS in high-risk patients was 12 months on GRANITE versus seven months in the control arm.
The population targeted by Gritstone’s most advanced program is a tough one. Metastatic colorectal cancer is the second most common cause of cancer death with up to 97% of patients categorized as metastatic microsatellite stable. These types of patients do not often benefit from checkpoint inhibitors, the company said, adding that their personalized neoantigen-directed vaccine could potentially drive efficacy in a metastatic “cold” tumor.
A cold tumor is surrounded by cells that suppress immune response to prevent T cells from attacking. J. Randolph Hecht, an investigator in the Phase II/III study, said GRANITE has the potential for benefit in not only MSS-CRC but other cold tumors as well.
The trial announcement celebrated the early trend in benefit for PFS and extended PFS benefit in high-risk patients. The biotech also pointed out it was able to manufacture a vaccine for each of the 39 patients in the treatment arm with a 100% success rate.
At the close of 2023, Gritstone projected its cash runway wouldn't take the company through 2024. After posting the Phase II/III data on Monday, Gritstone announced a public offering of $32.5 million.
In February 2023, the biotech cut 40% of its workforce following a delay of its Phase IIb study for a self-amplifying mRNA COVID-19 vaccineCOVID-19 vaccine, which cost the company funding from the U.S. Biomedical Advanced Research and Development Authority.
Kate Goodwin is a freelance life science writer based in Des Moines, Iowa. She can be reached at kate.goodwin@biospace.com and on LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.